Wellinks lands $10M Series B to scale predictive respiratory care

What's the deal? Wellinks, a New Haven-based cardiopulmonary care company, has secured $10 million in the first close of its Series B round. UMass Memorial Health and inside investors participated.

What's the endgame? Wellinks sells an FDA-cleared remote patient monitoring system, the Spire, which flags early physiologic changes tied to clinical deterioration. Its Health Tags monitor patients passively and can predict deterioration up to a week before symptoms appear.

Why now? The round builds on a multiyear relationship with UMass Memorial Health. The two organisations ran the Healthy at Home program, which found participants had more than 60% lower odds of 30-day hospital readmission compared with similar patients who did not take part.

What's the money for? Wellinks plans to expand its commercial footprint into broader patient populations, including rural and underserved communities. It also aims to sharpen its predictive capabilities and move into new conditions such as congestive heart failure.

"This investment represents validation of the solution we've built and the outcomes it delivers," said Jennifer Barretta, chief operating officer and interim chief executive officer of Wellinks.

Dr. Eric Dickson, chief executive officer at UMass Memorial Health, said the collaboration reflects "a shared commitment to advancing proactive, data-driven care."

The signal: The raise reflects growing investor and provider interest in remote monitoring that shifts chronic disease management out of hospitals and into the home. By pairing predictive data with earlier intervention, Wellinks is betting it can cut acute care use and total costs for a traditionally underserved patient group.

Image credit: Wellinks